Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].

Cayuela JM, Chomel JC, Coiteux V, Dulucq S, Escoffre-Barbe M, Etancelin P, Etienne G, Hayette S, Millot F, Nibourel O, Nicolini FE, Réa D; pour la France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) et le Groupe des biologistes moléculaires des hémopathies malignes (GBMHM).

Bull Cancer. 2019 Jul 25. pii: S0007-4551(19)30259-0. doi: 10.1016/j.bulcan.2019.05.011. [Epub ahead of print] Review. French.

PMID:
31353136
2.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

3.

Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.

Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, Choufi B, Rodriguez C, Frimat C, Plantier I, Stalnikiewicz L, Bemba M, Berthon C, Marolleau JP, Quesnel B, Preudhomme C, Duployez N.

Am J Hematol. 2019 Jan;94(1):E24-E27. doi: 10.1002/ajh.25328. Epub 2018 Nov 25. No abstract available.

PMID:
30358899
4.

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A.

Haematologica. 2018 May;103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22.

5.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia.

Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X.

Clin Cancer Res. 2017 Oct 15;23(20):6325-6335. doi: 10.1158/1078-0432.CCR-17-0007. Epub 2017 Jul 28.

6.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
7.

Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.

Duléry R, Nibourel O, Gauthier J, Elsermans V, Behal H, Coiteux V, Magro L, Renneville A, Marceau A, Boyer T, Quesnel B, Preudhomme C, Duhamel A, Yakoub-Agha I.

Bone Marrow Transplant. 2017 Apr;52(4):539-543. doi: 10.1038/bmt.2016.318. Epub 2017 Jan 9.

PMID:
28067876
8.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N.

J Clin Oncol. 2017 Jan 10;35(2):185-193. Epub 2016 Nov 14.

PMID:
28056203
9.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH.

Leukemia. 2017 Mar;31(3):555-564. doi: 10.1038/leu.2016.265. Epub 2016 Sep 30.

PMID:
27686867
10.

Absence of CALR mutations in JAK2-negative polycythemia.

Chauveau A, Nibourel O, Tondeur S, Paz DL, Mansier O, Paul F, Wemeau M, Preudhomme C, Lippert E, Ugo V; French Intergroup of Myeloproliferative Neoplasms.

Haematologica. 2017 Jan;102(1):e15-e16. doi: 10.3324/haematol.2016.154799. Epub 2016 Oct 6. No abstract available.

11.

Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR.

Abdelhamid E, Besbes S, Renneville A, Nibourel O, Helevaut N, Preudhomme C, Soua Z.

Tunis Med. 2016 Mar;94(3):190-7.

12.

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.

Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiègue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2016 Jun 7;8(34):57451-57459. doi: 10.18632/oncotarget.9917. eCollection 2017 Aug 22.

13.

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.

Charpentier A, Lebreton A, Rauch A, Bauters A, Trillot N, Nibourel O, Tintillier V, Wemeau M, Demory JL, Preudhomme C, Jude B, Lecompte T, Cambier N, Susen S.

Haematologica. 2016 Sep;101(9):e365-8. doi: 10.3324/haematol.2016.144279. Epub 2016 May 31. No abstract available.

14.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

Duployez N, Nibourel O, Ducourneau B, Grardel N, Boyer T, Bories C, Darre S, Coiteux V, Berthon C, Preudhomme C, Roche-Lestienne C.

Eur J Haematol. 2016 Oct;97(4):399-402. doi: 10.1111/ejh.12752. Epub 2016 Mar 26.

PMID:
26935241
15.

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine.

Desoutter J, Gay J, Berthon C, Ades L, Gruson B, Geffroy S, Plantier I, Marceau A, Helevaut N, Fernandes J, Bemba M, Stalnikiewicz L, Frimat C, Labreuche J, Nibourel O, Roumier C, Figeac M, Fenaux P, Quesnel B, Renneville A, Duhamel A, Preudhomme C.

Leukemia. 2016 Jun;30(6):1416-8. doi: 10.1038/leu.2015.314. Epub 2015 Nov 19. No abstract available.

PMID:
26582646
16.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.

Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, Doye E, Bertrand E, Geffroy S, Lepretre F, Nibourel O, Decambron A, Boyle EM, Renneville A, Tricot S, Daudignon A, Quesnel B, Duthilleul P, Preudhomme C, Leleu X.

Clin Cancer Res. 2016 Mar 15;22(6):1480-8. doi: 10.1158/1078-0432.CCR-15-0646. Epub 2015 Oct 21.

17.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C.

Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645.

18.

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

Smol T, Nibourel O, Marceau-Renaut A, Celli-Lebras K, Berthon C, Quesnel B, Boissel N, Terré C, Thomas X, Castaigne S, Dombret H, Preudhomme C, Renneville A.

Leuk Res. 2015 Dec;39(12):1443-7. doi: 10.1016/j.leukres.2015.09.021. Epub 2015 Oct 9.

PMID:
26467814
19.

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).

Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F.

Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898.

20.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.

Bibault JE, Figeac M, Hélevaut N, Rodriguez C, Quief S, Sebda S, Renneville A, Nibourel O, Rousselot P, Gruson B, Dombret H, Castaigne S, Preudhomme C.

Oncotarget. 2015 Sep 8;6(26):22812-21.

21.

A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study.

Cayuela JM, Mauté C, Fabre AL, Nibourel O, Dulucq S, Delabesse E, Villarèse P, Hayette S, Mozziconacci MJ, Macintyre E; GBMHM.

Clin Biochem. 2015 Oct;48(15):982-7. doi: 10.1016/j.clinbiochem.2015.04.004. Epub 2015 Apr 12.

PMID:
25872147
22.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terré C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H.

Haematologica. 2015 May;100(5):e196-9. doi: 10.3324/haematol.2014.115576. Epub 2014 Dec 31. No abstract available.

23.

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A.

Oncotarget. 2014 Aug 15;5(15):6280-8.

24.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E.

Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27.

25.

Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.

Mauté C, Nibourel O, Réa D, Coiteux V, Grardel N, Preudhomme C, Cayuela JM; GBMHM.

Clin Biochem. 2014 Sep;47(13-14):1333-6. doi: 10.1016/j.clinbiochem.2014.05.067. Epub 2014 Jun 8.

PMID:
24915631
26.

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.

Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C.

Oncotarget. 2014 Feb 28;5(4):916-32.

27.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.

Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.

Am J Hematol. 2014 Jun;89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8.

28.

Quantification of JAK2V617F mutation by next-generation sequencing technology.

Abdelhamid E, Figeac M, Renneville A, Quief S, Villenet C, Boyer T, Nibourel O, Coiteux V, Cassinat B, Lippert E, Helevaut N, Soua Z, Preudhomme C.

Am J Hematol. 2013 Jun;88(6):536-7. doi: 10.1002/ajh.23446. Epub 2013 May 13. No abstract available.

29.

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, Tricot S, Daudignon A, Galiègue-Zouitina S, Soenen V, Theisen O, Grardel N, Nibourel O, Roche-Lestienne C, Quesnel B, Duthilleul P, Preudhomme C, Leleu X.

Blood. 2013 May 30;121(22):4504-11. doi: 10.1182/blood-2012-06-436329. Epub 2013 Mar 26.

30.

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.

Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C; French ALFA group.

Am J Hematol. 2013 Apr;88(4):306-11. doi: 10.1002/ajh.23403. Epub 2013 Mar 5.

31.

Acute myeloid leukemia with translocation t(3;5): new molecular insights.

Dumézy F, Renneville A, Mayeur-Rousse C, Nibourel O, Labis E, Preudhomme C.

Haematologica. 2013 Apr;98(4):e52-4. doi: 10.3324/haematol.2012.082149. Epub 2013 Feb 12. No abstract available.

32.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
33.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Abdelhamid E, Preudhomme C, Helevaut N, Nibourel O, Gardin C, Rousselot P, Castaigne S, Gruson B, Berthon C, Soua Z, Renneville A.

Leuk Res. 2012 Mar;36(3):316-23. doi: 10.1016/j.leukres.2011.11.002. Epub 2011 Nov 29.

PMID:
22129478
34.

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy.

Rose C, Fournier M, Nibourel O, Herbaux C, Charpentier A, Renneville A, Pissard S, Badens C, Preudhomme C.

Leuk Res. 2011 Nov;35(11):e203-5. doi: 10.1016/j.leukres.2011.07.010. Epub 2011 Aug 9. No abstract available.

PMID:
21831427
35.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.

Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.

Leukemia. 2011 Dec;25(12):1918-21. doi: 10.1038/leu.2011.173. Epub 2011 Jul 15. No abstract available.

PMID:
21760594
36.

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.

Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, Preudhomme C; Fi-LMC group.

Leukemia. 2011 Oct;25(10):1661-4. doi: 10.1038/leu.2011.139. Epub 2011 Jun 3. No abstract available.

PMID:
21637286
37.

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C.

Blood. 2011 Mar 31;117(13):3696-7. doi: 10.1182/blood-2010-11-320937. No abstract available.

38.

High-throughput genomic analysis in Waldenström's macroglobulinemia.

Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiègue-Zouitina S, Manier S, Soenen V, Nibourel O, Duthilleul P, Fonseca R, Leleu X.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):106-8. doi: 10.3816/CLML.2011.n.021. Review.

PMID:
21454205
39.

Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.

Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pagès MP, Vasquez N, Dubois d'Enghien C, Larghero J, Peffault de Latour R, Rocha V, Dalle JH, Schneider P, Michallet M, Michel G, Baruchel A, Sigaux F, Gluckman E, Leblanc T, Stoppa-Lyonnet D, Preudhomme C, Socié G, Soulier J.

Blood. 2011 Apr 14;117(15):e161-70. doi: 10.1182/blood-2010-09-308726. Epub 2011 Feb 16.

40.

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.

Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G.

Blood. 2010 Dec 16;116(25):5638-49. doi: 10.1182/blood-2010-04-281600. Epub 2010 Oct 1.

41.

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.

Joha S, Dauphin V, Leprêtre F, Corm S, Nicolini FE, Roumier C, Nibourel O, Grardel N, Maguer-Satta V, Idziorek T, Figeac M, Laï JL, Quesnel B, Etienne G, Guilhot F, Lippert E, Preudhomme C, Roche-Lestienne C.

Leuk Res. 2011 Apr;35(4):448-58. doi: 10.1016/j.leukres.2010.07.012. Epub 2010 Aug 3.

PMID:
20684991
42.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C.

J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12.

PMID:
20625116
43.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C.

Blood. 2010 Aug 19;116(7):1132-5. doi: 10.1182/blood-2009-07-234484. Epub 2010 May 20.

44.

Waved aCGH: to smooth or not to smooth.

Leprêtre F, Villenet C, Quief S, Nibourel O, Jacquemin C, Troussard X, Jardin F, Gibson F, Kerckaert JP, Roumier C, Figeac M.

Nucleic Acids Res. 2010 Apr;38(7):e94. doi: 10.1093/nar/gkp1215. Epub 2010 Jan 13.

45.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, Philippe N, Thomas X, Dombret H, Preudhomme C.

Cancer. 2009 Aug 15;115(16):3719-27. doi: 10.1002/cncr.24442.

46.

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, Nibourel O, Pautas C, Reman O, Thomas X, Gardin C, Terré C, Castaigne S, Preudhomme C, Dombret H.

Blood. 2009 May 21;113(21):5090-3. doi: 10.1182/blood-2008-12-194704. Epub 2009 Mar 16.

47.

C/EBPA methylation is common in T-ALL but not in M0 AML.

Terriou L, Ben Abdelali R, Roumier C, Lhermitte L, de Vos J, Cornillet P, Nibourel O, Beldjord K, Dombret H, Leverger G, Asnafi V, Preudhomme C, Macintyre E.

Blood. 2009 Feb 19;113(8):1864-6; author reply 1866. doi: 10.1182/blood-2008-09-176909. No abstract available.

48.

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C.

Leukemia. 2008 May;22(5):915-31. doi: 10.1038/leu.2008.19. Epub 2008 Feb 21. Review.

PMID:
18288131
49.

Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.

Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C, Amouyel P, Cottel D, Castaigne S, Dombret H, Thomas X, Fenaux P, Preudhomme C; French alfa group.

Leukemia. 2008 Mar;22(3):655-7. Epub 2007 Sep 13. No abstract available.

PMID:
17851556
50.

[Beta(o)/beta(o) thalassemia with a mild phenotype].

Hémar C, Nibourel O, Maboudou P, Méreau-Richard C, Badens C, Rousseaux J, Rose C.

Ann Biol Clin (Paris). 2006 Jul-Aug;64(4):341-5. French.

Supplemental Content

Loading ...
Support Center